ASND Overview

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Wall Street analysts forecast ASND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASND is267.50 USD with a low forecast of 240.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ascendis Pharma A/S revenue for the last quarter amounts to 214.00M USD, increased 269.40 % YoY.

Ascendis Pharma A/S. EPS for the last quarter amounts to -1.00 USD, decreased -41.86 % YoY.

Ascendis Pharma A/S (ASND) has 879 emplpoyees as of January 31 2026.

Today ASND has the market capitalization of 14.00B USD.